SCHEMBL352178

SCHEMBL352178

[c]1ccc(-c2cccc3[c]cccc23)c2ccccc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2318595 0.93 CYP1A2 (0.32)
SCHEMBL152508 0.91 CYP1A2 (0.33)
SCHEMBL2274793 0.88 ALDH1A1 (0.40)
SCHEMBL2270433 0.88 ALDH1A1 (0.40)
SCHEMBL15987646 0.83 CYP1A2 (0.41)
SCHEMBL385879 0.83 METAP2 (0.38)
SCHEMBL20773996 0.83 HPRT1 (0.50)
SCHEMBL20774140 0.83 HPRT1 (0.50)
SCHEMBL2448398 0.82 ALDH1A1 (0.34)
SCHEMBL3783406 0.81 ALDH1A1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4349336-A1 COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS Genoscience Pharma (FR) 2024-04-10 EP disclosed
US-11261189-B2 Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases GENOSCIENCE PHARMA (FR) 2022-03-01 US disclosed
EP-3846814-A1 SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES Genoscience Pharma (FR) 2021-07-14 EP disclosed
EP-3452465-B1 SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES GENOSCIENCE PHARMA (FR) 2020-11-04 EP disclosed
US-20200079781-A1 Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases GENOSCIENCE PHARMA (FR) 2020-03-12 US disclosed
EP-3620164-A1 SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES Genoscience Pharma SAS (FR) 2020-03-11 EP disclosed
US-10586929-B2 Solvent-resistant hole transport layers LG CHEM, LTD. (KR) 2020-03-10 US disclosed
US-10577362-B2 Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases GENOSCIENCE PHARMA (FR) 2020-03-03 US disclosed
US-20190144437-A1 SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES GENOSCIENCE PHARMA (FR) 2019-05-16 US disclosed
EP-3452465-A1 SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES Genoscience Pharma SAS (FR) 2019-03-13 EP disclosed
US-8497495-B2 Electroactive materials E I DU PONT DE NEMOURS AND COMPANY (US) 2013-07-30 US disclosed
US-20120187382-A1 ELECTRONIC DEVICES HAVING LONG LIFETIME E.I. DUPONT DE NEMOURS AND COMPANY (US) 2012-07-26 US disclosed
US-20120065432-A1 ELECTROACTIVE MATERIALS E.I DU PONT DE NEMOURS AND COMPANY (US) 2012-03-15 US disclosed
US-20120013245-A1 ELECTROACTIVE MATERIALS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-01-19 US disclosed
US-8063399-B2 Electroactive materials E. I. DU PONT DE NEMOURS AND COMPANY (US) 2011-11-22 US disclosed
US-20110095269-A1 ELECTROACTIVE MATERIALS E. I. DU PONT DE NEMOURS AND COMPANY 2011-04-28 US disclosed
US-20100252819-A1 ELECTROACTIVE MATERIALS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-10-07 US disclosed
US-7271406-B2 Electron transport agents for organic electronic devices 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-09-18 US disclosed
EP-0152372-B1 SUBSTITUTED UNSATURATED BICYCLIC IMIDES AND THEIR POLYMERS CIBA-GEIGY AG (CH) 1991-12-27 EP disclosed
EP-0152372-A2 Substituted unsaturated bicyclic imides and their polymers CIBA-GEIGY AG (CH) 1985-08-21 EP disclosed